🔗 Share this article

While America continues making sweeping adjustments to its immunization schedules, an unexpected name has surfaced in a surprising turn: Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by questioning COVID-19 shots in the pandemic and has focused upon alleged deaths after COVID-19 immunization in her short tenure at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Program

Public health authorities planned to announce radical revisions to the childhood immunization program earlier this month, bringing the US with the Danish immunization schedule, according to reports – a major change that would place the US out of step with a large portion of the international standard with insufficient data for benefit. The announcement has been postponed until the new year.

Rather than the top vaccines chief, Dr. Høeg is set to speak at the gathering. She was recently named interim head of the FDA’s CDER, the fifth individual to lead the center this year.

A Shift at the FDA

Høeg's temporary position might represent a closer partnership between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad consolidate power at the agency – and it signals a renewed priority upon dismantling previously authorized immunizations at the FDA.

The new acting director has repeatedly called for ending specific childhood vaccine recommendations in the US in order to be more similar to Denmark's approach, a country with nationalized medicine and a population roughly the population of the state of Wisconsin.

So far public appearances, she has continued to focus on immunizations – usually the purview of Dr. Prasad, head of the FDA’s CBER – as opposed to medication approval.

Concerns Over Expertise

The appointee has little discernible experience in medication creation, oversight or management, which has been typical for former leaders of the CBER. She has served at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for leading the drug-regulation department, remarked Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in running a sizeable institution. She lacks background in pharmaceutical oversight.”

Previous commissioners of CBER would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, noted a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that former directors who ran the center have had.”

This division has an immense workload at the agency, Woodcock pointed out.

“Everybody just focuses on the novel medication approvals, but the generic drug division approves numerous generic drugs. There is also a biosimilars division, non-prescription drug unit and so forth, and each of these need to be supervised,” Dr. Woodcock noted. “The area you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

There is also, a major administrative component to the role, which oversees in excess of 5,000 staff members. “It is a massive leadership role, if you execute it properly,” Woodcock concluded.

Response and Contentious Programs

In response to questions about Høeg’s credentials and whether this appointment represents greater collaboration among agency officials on immunizations, a representative said that the “concerns rely on inaccurate presumptions”.

“Her resume matches the responsibilities of her position,” the spokesperson explained, pointing to the time Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg inherits the commissioner’s recently launched priority voucher program, a controversial rapid medication authorization process that allegedly concerned her former heads. “How are these medications being chosen for this expedited pathway? Who takes the calls?” Dr. Howard questioned. “There is a lot of confidentiality occurring at the agency right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards less stringent rules of pharmaceuticals, aside from vaccines.”

Established Track Record on Vaccines

Regarding vaccines, Høeg has a clearer, if troubling, history, critics said. She published a analysis using unconfirmed crowd-sourced reports to assess the rate of myocarditis after Covid immunization. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to suggest Covid vaccinations are more dangerous than they are.

Part of her “desired changes” for the current federal leadership featured revising regulations for new vaccines and halting “unnecessary” vaccines, she stated post-election on a podcast. At the agency, Dr. Høeg has according to sources proposed preventing adolescent males from receiving Covid vaccines.

“She’s an thorough ideologue who begins with her conclusions and reverse-engineers to fit the science in a very misleading, untruthful way,” Dr. Howard stated.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow contrarians, {like|